Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
High immature granulocytes (IG) can occur in leukemia, but an elevated IG count is far more often a sign of infection, inflammation, tissue injury, pregnancy, steroid use, or recovery from surgery than of blood cancer. Leukemia is usually suspected when a high IG level appears alongside other red flags, such as blasts on the blood smear, abnormal white cell counts, anemia, low platelets, unexplained fevers, night sweats, easy bruising, bone pain, or swollen lymph nodes. The size of the increase, whether it persists on repeat testing, and the rest of your CBC results all change what the finding means. There are several important factors to consider, so see below to understand more about what your result may indicate and when further testing is warranted.
If you are trying to make sense of an abnormal lab value and decide whether it needs urgent attention, a free, instant online symptom check can help you organize your symptoms, see which conditions best match your pattern, and walk into your next appointment with clear questions and next steps.
Last reviewed for medical accuracy: 09/14/2026
When your blood test shows elevated immature granulocytes, it’s natural to wonder what it means. Immature granulocytes are young white blood cells that normally develop in the bone marrow and mature before entering the bloodstream. Occasionally, these cells appear in the blood, and while this can be alarming, it isn’t always a sign of leukemia. This guide explains what immature granulocytes are, why they can be elevated, and when you should consider further evaluation.
In a healthy person, virtually all granulocytes in circulation are mature. When immature granulocytes appear in a peripheral blood sample, it’s called a “left shift” or an “increased IG count.”
Your laboratory report may flag the IG% or IG# as “high” if it exceeds the normal range. However, a single elevated result doesn’t automatically point to leukemia.
Acute infections
Inflammation and stress
Bone marrow recovery
Myeloproliferative disorders
Medications
Severe hemolysis or bleeding
Leukemia is a cancer of the blood-forming tissues, often involving an overproduction of abnormal white cells. But an elevated immature granulocyte count alone is not a definitive sign of leukemia. Here’s how to interpret findings:
Acute leukemias (AML, ALL)
Chronic leukemias (CML, CLL)
Key point: A mild to moderate rise in immature granulocytes (e.g., IG% of 1–3%) is far more likely related to infection or inflammation than leukemia. In contrast, leukemia generally presents with blasts, anemia, low platelets or very high total white cell counts.
Consider further evaluation if you have:
If you’re unsure about your symptoms or blood test results, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you understand possible causes and whether you should see a healthcare professional.
A high immature granulocyte count alone does not diagnose leukemia. A thorough work-up typically includes:
Complete blood count (CBC) with differential
Peripheral blood smear
Bone marrow biopsy and aspiration
Genetic and molecular tests
Other laboratory studies
Because immature granulocytes increase in many scenarios, doctors also consider:
Accurate diagnosis depends on combining lab data with your medical history, physical exam and sometimes imaging studies.
Any of the following warrants prompt medical attention:
Even if you suspect your elevated immature granulocytes are from a benign cause, discuss any concerning results with your doctor. Early evaluation ensures that conditions like leukemia or severe infections are not missed.
Your health matters. If you have any unexplained symptoms or persistently abnormal blood tests, consult a healthcare professional for a full evaluation.
(References)
* Grignani F. Chronic myelogenous leukemia. Crit Rev Oncol Hematol. 1985;4(1):31-66. PMID: 3902263.
* Francisconi CF, Caldas RJ, Oliveira Martins LJ, Fischer Rubira CM, da Silva Santos PS. Leukemic Oral Manifestations and their Management. Asian Pac J Cancer Prev. 2016;17(3):911-5. doi: 10.7314/apjcp.2016.17.3.911. PMID: 27039811.
* Chen J, Cheng J, Yi J, Xie B, Lin L, Liu Z, Zhao H, Wang B, Ai Z, Yang Y, Wei H. Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide. Leuk Res. 2016 Nov;50:116-122. doi: 10.1016/j.leukres.2016.10.003. Epub 2016 Oct 3. PMID: 27736728.
* Nowacka JD, Baumgartner C, Pelorosso C, Roth M, Zuber J, Baccarini M. MEK1 is required for the development of NRAS-driven leukemia. Oncotarget. 2016 Dec 6;7(49):80113-80130. doi: 10.18632/oncotarget.12555. PMID: 27741509; PMCID: PMC5348309.
* Kozako T, Mellini P, Ohsugi T, Aikawa A, Uchida YI, Honda SI, Suzuki T. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines. BMC Cancer. 2018 Aug 6;18(1):791. doi: 10.1186/s12885-018-4710-1. Epub 2018 Aug 6. PMID: 30081901; PMCID: PMC6091197.
* Surapally S, Jayaprakasam M, Verma RS. Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia. Pharmacol Rep. 2020 Aug;72(4):1032-1046. doi: 10.1007/s43440-020-00073-7. Epub 2020 Mar 5. PMID: 32141025.
* Qiang X, Chen S, Chen X. Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis. Br J Haematol. 2022 Nov;199(4):475. doi: 10.1111/bjh.18428. Epub 2022 Aug 23. PMID: 35996972.
* Núñez-Sánchez MÁ, Martínez-Sánchez MA, Verdejo-Sánchez M, García-Ibáñez P, Oliva Bolarín A, Ramos-Molina B, Moreno DA, Ruiz-Alcaraz AJ. Anti-Leukemic Activity of Brassica-Derived Bioactive Compounds in HL-60 Myeloid Leukemia Cells. Int J Mol Sci. 2022 Nov 2;23(21). doi: 10.3390/ijms232113400. Epub 2022 Nov 2. PMID: 36362202; PMCID: PMC9657236.
* Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, Tomalin LE, Cruz-Rodriguez N, Wang T, Olszewska M, Olivier E, Jaud M, Nadorp B, Kroger B, Hu F, Silverman L, Chung SS, Wagenblast E, Chaligne R, Eisfeld AK, Demircioglu D, Landau DA, Lito P, Papaemmanuil E, DiNardo CD, Hasson D, Konopleva M, Papapetrou EP. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024 Dec;636(8041):241-250. doi: 10.1038/s41586-024-08137-x. Epub 2024 Oct 30. PMID: 39478230; PMCID: PMC11618090.
* Deschamps P, Wacheux M, Gosseye A, Morabito M, Pagès A, Lyne AM, Alfaro A, Rameau P, Imanci A, Chelbi R, Marchand V, Renneville A, Patnaik MM, Lapierre V, Badaoui B, Wagner-Ballon O, Berthon C, Braun T, Willekens C, Itzykson R, Fenaux P, Thépot S, Etienne G, Elvira-Matelot E, Porteu F, Droin N, Perié L, Laplane L, Solary E, Selimoglu-Buet D. CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia. J Clin Invest. 2024 Sep 17;134(22). doi: 10.1172/JCI180738. Epub 2024 Sep 17. PMID: 39545419; PMCID: PMC11563679.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.